跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
APO-FLUTICASONE HFA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
APO-FLUTICASONE HFA
Authorized
STANDARD
APO-FLUTICASONE HFA
Apotex Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
67ab2a4c56211974
Company
Apotex Inc
Type
Standard
Approval Details
Approval Id
67ab2a4c56211974
Drug Approval Canada Name
APO-FLUTICASONE HFA
Product Name
APO-FLUTICASONE HFA
Status
Marketed
Status Date
2022-11-22
Original Market Date
2022-11-22
Din
02526557
Drug Class
Human
Dosage Form
Metered-Dose Aerosol
Route Of Administration
Oral , Inhalation
Schedule
Prescription
Ahfs
68:04.00
Atc Original
R03BA05 FLUTICASONE
Atc Name
r 03 ba 05
Aig Number
0124685004
Company Name
Apotex Inc
Company Address
150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path
/organization/apotex-inc
Company Information
Pharmaceutical Company Name
Apotex Inc
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
150 Signet Dr
Active Ingredients
FLUTICASONE PROPIONATE
125 MCG / ACT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
67ab2a4c56211974
Type
Standard
Back to Health Canada Approvals